Protein cocrystallization molecules originating from in vitro selected macrocyclic peptides

Current Opinion in Structural Biology

Volumn 26, Issue 1, 2014, Pages 24-31

  Hipolito, Christopher J ^a   Bashiruddin, Nasir K ^a   Suga, Hiroaki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CYCLOPEPTIDE; MACROCYCLIC PEPTIDE LIGAND; MESSENGER RNA; MULTIDRUG AND TOXIC COMPOUND EXTRUSION TRANSPORTER; PEPTIDE MAD1; PEPTIDE MAD10; PEPTIDE MAD3; PEPTIDE MAD5; PEPTIDE MAL3; PEPTIDE MAL6; TRANSFER RNA; UNCLASSIFIED DRUG; LIGAND; MACROCYCLIC COMPOUND; PEPTIDE; PROTEIN;

AMINO ACID SEQUENCE; BINDING AFFINITY; BINDING SITE; COMPLEX FORMATION; CRYSTAL STRUCTURE; CRYSTALLIZATION; HYDROPHILICITY; IN VITRO STUDY; MOLECULAR MODEL; PEPTIDE ANALYSIS; PEPTIDE LIBRARY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN COCRYSTALLIZATION; PROTEIN PROCESSING; PYROCOCCUS FURIOSUS; REVIEW; CHEMISTRY; METABOLISM; MOLECULAR GENETICS; PROCEDURES;

AMINO ACID SEQUENCE; CRYSTALLIZATION; LIGANDS; MACROCYCLIC COMPOUNDS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEINS;

EID: 84897061191     PISSN: 0959440X     EISSN: 1879033X     Source Type: Journal    
DOI: 10.1016/j.sbi.2014.03.001     Document Type: Review

References (45)

1. Warke A., Momany C. Addressing the protein crystallization bottleneck by cocrystallization. Cryst Growth Des 2007, 7:2219-2225.
2. McPherson A., Cudney B. Searching for silver bullets: an alternative strategy for crystallizing macromolecules. J Struct Biol 2006, 156:387-406.
3. Paduch M., Koide A., Uysal S., Rizk S.S., Koide S., Kossiakoff A.A. Generating conformation-specific synthetic antibodies to trap proteins in selected functional states. Methods 2013, 60:3-14.
4. Skerra A. Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J 2008, 275:2677-2683.
5. Skerra A. Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 2007, 18:295-304.
6. Boersma Y.L., Plückthun A. DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr Opin Biotechnol 2011, 22:849-857.
7. Löfblom J., Feldwisch J., Tolmachev V., Carlsson J., Ståhl S., Frejd F.Y. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010, 584:2670-2680.
8. Gilbreth R.N., Koide S. Structural insights for engineering binding proteins based on non-antibody scaffolds. Curr Opin Struct Biol 2012, 22:413-420.
9. Bukowska M.A., Grütter M.G. New concepts and aids to facilitate crystallization. Curr Opin Struct Biol 2013, 23:409-416.
10. Wurch T., Pierré A., Depil S. Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. Trends Biotechnol 2012, 30:575-582.
11. Sennhauser G., Amstutz P., Briand C., Storchenegger O., Grütter M.G. Drug export pathway of multidrug exporter AcrB revealed by DARPin inhibitors. PLoS Biol 2007, 5:e7.
12. +-coupled, substrate-bound MATE multidrug transporter. Proc Natl Acad Sci USA 2013, 110:2099-2104.
13. Seeger M.A., Mittal A., Velamakanni S., Hohl M., Schauer S., Salaa I., Grütter M.G., van Veen H.W. Tuning the drug efflux activity of an ABC transporter in vivo by in vitro selected DARPin binders. PLoS One 2012, 7:e37845.
14. Mittal A., Böhm S., Grütter M.G., Bordignon E., Seeger M.A. Asymmetry in the homodimeric ABC transporter MsbA recognized by a DARPin. J Biol Chem 2012, 287:20395-20406.
15. Seeger M.A., Zbinden R., Flütsch A., Gutte P.G.M., Engeler S., Roschitzki-Voser H., Grütter M.G. Design, construction, and characterization of a second-generation DARPin library with reduced hydrophobicity. Protein Sci 2013, 22:1239-1257.
16. Tanaka Y., Hipolito C.J., Maturana A.D., Ito K., Kuroda T., Higuchi T., Katoh T., Kato H.E., Hattori M., Kumazaki K., Tsukazaki T., Ishitani R., Suga H., Nureki O. Structural basis for the drug extrusion mechanism by a MATE multidrug transporter. Nature 2013, 496:247-251.
17. Hipolito C.J., Tanaka Y., Katoh T., Nureki O., Suga H. A macrocyclic peptide that serves as a cocrystallization ligand and inhibits the function of a MATE family transporter. Molecules 2013, 18:10514-10530.
18. Giordanetto F., Kihlberg J. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?. J Med Chem 2014, 57:278-295.
19. Driggers E.M., Hale S.P., Lee J., Terrett N.K. The exploration of macrocycles for drug discovery - an underexploited structural class. Nat Rev Drug Discov 2008, 7:608-624.
20. Marsault E., Peterson M.L. Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. J Med Chem 2011, 54:1961-2004.
21. Frost J.R., Smith J.M., Fasan R. Design, synthesis, and diversification of ribosomally derived peptide macrocycles. Curr Opin Struct Biol 2013, 23:571-580.
22. Roberts R., Szostak J. RNA-peptide fusions for the in vitro selection of peptides and proteins. Proc Natl Acad Sci USA 1997, 94:12297-12302.
23. Nemoto N., Miyamoto-sato E., Husumi Y., Yanagawa H. In vitro virus: bonding of mRNA bearing puromycin at the 3'-terminal end to the C-terminal end of its encoded protein on the ribosome in vitro. FEBS Lett 1997, 414:405-408.
24. Hipolito C.J., Suga H. Ribosomal production and in vitro selection of natural product-like peptidomimetics: the FIT and RaPID systems. Curr Opin Chem Biol 2012, 16:196-203.
25. Goto Y., Ohta A., Sako Y., Yamagishi Y., Murakami H., Suga H. Reprogramming the translation initiation for the synthesis of physiologically stable cyclic peptides. ACS Chem Biol 2008, 3:120-129.
26. Sako Y., Goto Y., Murakami H., Suga H. Ribosomal synthesis of peptidase-resistant peptides closed by a nonreducible inter-side-chain bond. ACS Chem Biol 2008, 3:241-249.
27. Yamagishi Y., Ashigai H., Goto Y., Murakami H., Suga H. Ribosomal synthesis of cyclic peptides with a fluorogenic oxidative coupling reaction. ChemBioChem 2009, 10:1469-1472.
28. Goto Y., Iwasaki K., Torikai K., Murakami H., Suga H. Ribosomal synthesis of dehydrobutyrine- and methyllanthionine-containing peptides. Chem Commun 2009, 23:3419-3421.
29. Kawakami T., Ohta A., Ohuchi M., Ashigai H., Murakami H., Suga H. Diverse backbone-cyclized peptides via codon reprogramming. Nat Chem Biol 2009, 5:888-890.
30. Ohshiro Y., Nakajima E., Goto Y., Fuse S., Takahashi T., Doi T., Suga H. Ribosomal synthesis of backbone-macrocyclic peptide containing γ-amino acids. ChemBioChem 2011, 12:1183-1187.
31. Yamagishi Y., Shoji I., Miyagawa S., Kawakami T., Katoh T., Goto Y., Suga H. Natural product-like macrocyclic N-methyl-peptide inhibitors against a ubiquitin ligase uncovered from a ribosome-expressed de novo library. Chem Biol 2011, 18:1562-1570.
32. Morimoto J., Hayashi Y., Suga H. Discovery of macrocyclic peptides armed with a mechanism-based warhead: isoform-selective inhibition of human deacetylase SIRT2. Angew Chem Int Ed 2012, 51:3423-3427.
33. Hayashi Y., Morimoto J., Suga H. In vitro selection of anti-Akt2 thioether-macrocyclic peptides leading to isoform-selective inhibitors. Chem Biol 2012, 7:607-613.
34. +-coupled multidrug extrusion by a MATE transporter. Nat Struct Mol Biol 2013, 20:1310-1317.
35. He X., Szewczyk P., Karyakin A., Evin M., Hong X., Zhang Q., Chang G. Structure of a cation-bound multidrug and toxic compound extrusion transporter. Nature 2010, 467:991-994.
36. Iwasaki K., Goto Y., Katoh T., Suga H. Selective thioether macrocyclization of peptides having the N-terminal 2-chloroacetyl group and competing two or three cysteine residues in translation. Org Biomol Chem 2012, 10:5783-5786.
37. 2 adrenoceptor. Nature 2011, 469:175-180.
38. 2-adrenoceptor stabilized by an engineered nanobody. Nature 2013, 502:575-579.
39. Kruse A.C., Ring A.M., Manglik A., Hu J., Hu K., Eite K., Hübner H., Pardon E., Valant C., Sexton P.M., Christopoulos A., Felder C.C., Gmeiner P., Steyaert J., Weis W.I., Garcia K.C., Wess J., Kobilka B.K. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 2013, 504:101-106.
40. Hino T., Arakawa T., Iwanari H., Yurugi-Kobayashi T., Ikeda-Suno C., Nakada-Nakura Y., Kusano-Arai O., Weyand S., Shimamura T., Nomura N., et al. G-protein-coupled receptor inactivation by an allosteric inverse-agonist antibody. Nature 2012, 482:237-240.
41. Hino T., Iwata S., Murata T. Generation of functional antibodies for mammalian membrane protein crystallography. Curr Opin Struct Biol 2013, 23:563-568.
42. De Genst E., Silence K., Decanniere K., Conrath K., Loris R., Kinne J., Muyldermans S., Wyns L. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci USA 2006, 103:4586-4591.
43. Angelini A., Cendron L., Chen S., Touati J., Winter G., Zanotti G., Heinis C. Bicyclic peptide inhibitor reveals large contact interface with a protease target. ACS Chem Biol 2012, 7:817-821.
44. Chen S., Morales-Sanfrutos J., Angelini A., Cutting B., Heins C. Structurally diverse cyclisation linkers impose different backbone conformations in bicyclic peptides. ChemBioChem 2012, 13:1032-1038.
45. Ishizawa T., Kawakami T., Reid P.C., Murakami H. TRAP display: a high-speed selection method for the generation of functional polypeptides. J Am Chem Soc 2013, 135:5433-5440.